Takeda presents Phase III data for Entyvio in UC and Crohn's Disease

2 October 2014

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) today announced new data from a Phase III study of Entyvio (vedolizumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).

Data from the ongoing open-label extension study of GEMINI LTS (Long-Term Safety) will be released as oral presentations during the 21st United European Gastroenterology Week (UEGW) in Vienna, Austria.

Two of the abstracts demonstrate that the efficacy observed in vedolizumab Phase III induction and maintenance trials of 52 weeks was maintained over the course of an additional 52 weeks of open label follow up.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK